Desiree Gonzalez

Dr. Desiree Gonzalez


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JLJosé David Celdrán López
José David Celdrán López
LHLawrence Humphreys
Lawrence Humphreys
DGDesiree Gonzalez
Desiree Gonzalez
CSCristina Soto-Sánchez
Cristina Soto-Sánchez
GNGema Martínez Navarrete
Gema Martínez Navarrete
EFEduardo Buglioni Fernandez
Eduardo Buglioni Fernandez
Gene therapy and optogenetics are becoming promising tools for treating several nervous system pathologies. Currently, most of these approaches use viral vectors to transport the genetic material inside the cells, but viruses present some potential risks, such as marked immunogenicity, insertional mutagenesis, and limited insert gene size. In this framework, non-viral nanoparticles, such as niosomes, are emerging as possible alternative tools to deliver genetic material, avoiding the aforementioned problems. To determine their suitability as vectors for optogenetic therapies in this work, we tested three different niosome formulations combined with three optogenetic plasmids in rat cortical neurons in vitro. All niosomes tested successfully expressed optogenetic channels, which were dependent on the ratio of niosome to plasmid, with higher concentrations yielding higher expression rates. However, we found changes in the dendritic morphology and electrophysiological properties of transfected cells, especially when we used higher concentrations of niosomes. Our results highlight the potential use of niosomes for optogenetic applications and suggest that special care must be taken to achieve an optimal balance of niosomes and nucleic acids to achieve the therapeutic effects envisioned by these technologies.

19 December 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JLJosé David Celdrán López
José David Celdrán López
LHLawrence Humphreys
Lawrence Humphreys
MVMaria Jose Verdú
Maria Jose Verdú
DGDesiree Gonzalez
Desiree Gonzalez
CSCristina Soto-Sánchez
Cristina Soto-Sánchez
EFEduardo Buglioni Fernandez
Eduardo Buglioni Fernandez
Background: Gene therapy has experienced significant development since its origin decades ago, resulting in therapies for a wide range of diseases. In this context, optogenetics has emerged as a promising therapy for treating diseases in a precise spatiotemporal way using light. Transporting optogenetic genes to target cells is achieved using viral vectors, specifically AAV vectors. These vectors present limited cargo capacity, and a large percentage of the population carries AAV neutralizing antibodies. In this regard, lipid nanoparticles can overcome some of the previously mentioned problems of AAV vectors, making them prime candidates for optogenetic delivery. Methods: In this study, we evaluated their suitability for the delivery of the ChrimsonR plasmid in neurons in vitro. Results: In rat cortical neurons, in most of the concentrations tested, there was no reduction in several neuron morphological parameters that we measured when compared to another non-viral nanoparticle called lipofectamine. Transfection efficiency was significantly higher compared to lipofectamine in almost all treatments. Further in vitro analysis showed that electrophysiological parameters were altered, with reduced signal amplitudes; however, cell viability assays showed no decline in cell viability. Conclusions: These results demonstrate that lipid nanoparticles represent a promising non-viral platform for optogenetic delivery, though formulation optimization is required to achieve full functional efficacy.